Novo Nordisk’s Ozempic® Lists on the Ontario Provincial Formulary

Published on
By : dLife Editors

Novo Nordisk announced that Ozempic (semaglutide injection) is now publicly reimbursed in the province of Ontario for adults living with Type 2 diabetes.

Ozempic is available through many private insurance plans and publicly reimbursed through the following national and provincial government-sponsored drug benefit programs:

  • Non-Insured Health Benefits Program
  • Alberta
  • Prince Edward Island
  • Ontario
Novo Nordisk Canada Inc

Ozempic® (semaglutide injection) Source: Novo Nordisk Canada Inc.

Ozempic is a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated alongside diet and exercise to improve glycemic control in adults with Type 2 diabetes when metformin is inappropriate.

Ozempic can also be used with metformin, sulfonylurea and basal insulin with metformin.

This announcement follows the regulatory approval of Ozempic in January of 2018. Ozempic was extensively studied in the SUSTAIN clinical trial program, which involved more than 8,000 adults with Type 2 diabetes.

In the SUSTAIN program, Ozempic was studied in combination with oral antidiabetic agents and basal insulin.

“Having public access to effective treatment options is essential for people living with Type 2 diabetes,” explains Dr. Ronald Goldenberg, an endocrinologist affiliated with LMC Healthcare and North York General Hospital.

“When left uncontrolled, diabetes can cause serious health problems that can negatively impact a person’s quality of life. Being able to prescribe Ozempic, which patients only need to take once a week, is an important step in helping to control the condition and reduce those risks,” he added.

For information about Ozempic, including important safety information, please visit or

Novo Nordisk Canada Inc.


1. Novo Nordisk. (2019, September 30). OZEMPIC® is now listed on the Ontario provincial formulary for adults living with Type 2 diabetes. PR Newswire. Retrieved October 1, 2019, from